Rigel Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RIGL)

$3.56 -0.01 (-0.28 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$3.57
Today's Range$3.41 - $3.69
52-Week Range$1.94 - $4.47
Volume8.14 million shs
Average Volume1.25 million shs
Market Capitalization$544.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3

About Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals logoRigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100

Debt

Debt-to-Equity RatioN/A
Current Ratio4.64%
Quick Ratio4.64%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.38 million
Price / Sales25.59
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book6.36

Profitability

Trailing EPS($0.59)
Net Income$-69,210,000.00
Net Margins-354.14%
Return on Equity-102.26%
Return on Assets-80.57%

Miscellaneous

Employees77
Outstanding Shares146,490,000

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The biotechnology company had revenue of $0.90 million for the quarter. Rigel Pharmaceuticals had a negative return on equity of 102.26% and a negative net margin of 354.14%. The firm's revenue was down 76.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) EPS. View Rigel Pharmaceuticals' Earnings History.

When will Rigel Pharmaceuticals make its next earnings announcement?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Rigel Pharmaceuticals.

Where is Rigel Pharmaceuticals' stock going? Where will Rigel Pharmaceuticals' stock price be in 2017?

4 Wall Street analysts have issued 1 year price objectives for Rigel Pharmaceuticals' shares. Their predictions range from $5.00 to $7.00. On average, they expect Rigel Pharmaceuticals' stock price to reach $5.75 in the next twelve months. View Analyst Ratings for Rigel Pharmaceuticals.

What are Wall Street analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "Commercial in 2018. Fostamatinib has a PDUFA date of April 17, 2018 for its application in ITP. With over 5,000 patient-years of treatment experience and a robust Phase 3 clinical package, we anticipate a positive decision in April. Rigel has begun pre-commercial activities for a potential launch and outlined its plans for a full commercial team of 50-60 individuals. Based on the mixed efficacy of currently available treatments, fragmentation of the therapeutic landscape, and concentration of prescribing physicians (3,000 hematologists and hematologist- oncologists), we believe Rigel will be successful at commercializing the drug." (12/14/2017)
  • 2. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (11/11/2017)
  • 3. Jefferies Group LLC analysts commented, "RIGL is on track to submit an NDA for fosta in ITP in 1Q17; next major catalyst could be FDA acceptance by ~May given mixed Ph3 data & limited FDA interactions following Ph3 data. YE16 cash of ~$75M, plus net proceeds of $43M from recent offering, should be sufficient at least for next 12 months including pre-commercial activities, per RIGL. If fosta is approved in ITP, we see >50% upside to our current PT of $5." (3/8/2017)
  • 4. BMO Capital Markets analysts commented, "We remain focused on fostamatinib's pending NDA submission, which we believe supports approval given clear and consistent benefit in ITP, despite one pivotal trial missing statistical significance. We believe reaching an FDA Adcom would be a positive event, as a panel of clinicians would likely recommend approval. Additionally, we believe the fostamatinib addressable patient population is larger than the 18% stable response rate, as real world use would include patients who maintain platelet counts greater than 30K/ul, according to physician feedback. We rate RIGL shares Outperform." (3/8/2017)

Are investors shorting Rigel Pharmaceuticals?

Rigel Pharmaceuticals saw a increase in short interest in November. As of November 30th, there was short interest totalling 8,879,012 shares, an increase of 26.5% from the November 15th total of 7,018,574 shares. Based on an average trading volume of 1,119,131 shares, the days-to-cover ratio is currently 7.9 days. Currently, 6.3% of the shares of the company are sold short.

Who are some of Rigel Pharmaceuticals' key competitors?

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:

  • Raul R Rodriguez, President, Chief Executive Officer, Director (Age 55)
  • Ryan D. Maynard, Chief Financial Officer and Executive Vice President (Age 45)
  • Dolly A. Vance, Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary (Age 50)
  • Eldon C. Mayer III, Executive Vice President, Chief Commercial Officer
  • Anne-Marie Duliege M.D., Chief Marketing Officer (Age 54)
  • Keith A. Katkin, Director (Age 44)
  • Brian Kotzin M.D., Director
  • Gregg Lapointe, Director
  • Bradford S. Goodwin, Independent Director (Age 60)
  • Gary A. Lyons, Independent Director (Age 66)

Who owns Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (0.95%), Candriam Luxembourg S.C.A. (0.87%), Macquarie Group Ltd. (0.51%), Wells Fargo & Company MN (0.28%), Crestline Management LP (0.22%) and NJ State Employees Deferred Compensation Plan (0.23%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Donald G Payan and Ryan D Maynard. View Institutional Ownership Trends for Rigel Pharmaceuticals.

Who sold Rigel Pharmaceuticals stock? Who is selling Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Crestline Management LP, Dimensional Fund Advisors LP, NJ State Employees Deferred Compensation Plan, JPMorgan Chase & Co. and California State Teachers Retirement System. Company insiders that have sold Rigel Pharmaceuticals company stock in the last year include Anne-Marie Duliege and Ryan D Maynard. View Insider Buying and Selling for Rigel Pharmaceuticals.

Who bought Rigel Pharmaceuticals stock? Who is buying Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Macquarie Group Ltd., Candriam Luxembourg S.C.A. and SG Americas Securities LLC. View Insider Buying and Selling for Rigel Pharmaceuticals.

How do I buy Rigel Pharmaceuticals stock?

Shares of Rigel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of Rigel Pharmaceuticals stock can currently be purchased for approximately $3.56.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $544.95 million and generates $20.38 million in revenue each year. The biotechnology company earns $-69,210,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Rigel Pharmaceuticals employs 77 workers across the globe.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]


MarketBeat Community Rating for Rigel Pharmaceuticals (RIGL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rigel Pharmaceuticals (NASDAQ:RIGL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.50$6.60$6.40$6.40
Price Target Upside: 82.07% upside70.10% upside149.03% upside130.22% upside

Rigel Pharmaceuticals (NASDAQ:RIGL) Consensus Price Target History

Price Target History for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$6.00HighView Rating Details
12/11/2017HC WainwrightSet Price TargetBuy$7.00HighView Rating Details
10/4/2017Jefferies GroupReiterated RatingBuy$5.00MediumView Rating Details
10/2/2017BMO Capital MarketsReiterated RatingBuy$5.00LowView Rating Details
11/2/2016Piper Jaffray CompaniesSet Price TargetBuy$11.00N/AView Rating Details
8/3/2016J P Morgan Chase & CoReiterated RatingBuy$5.00N/AView Rating Details
4/23/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) Earnings History and Estimates Chart

Earnings by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ RIGL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($0.13)N/AView Earnings Details
11/7/2017Q3 2017($0.15)($0.14)$0.90 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.15)($0.16)$2.05 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.12)($0.13)$4.30 million$3.58 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.17)($0.16)$4.25 million$3.00 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.24)$3.97 million$3.76 millionViewListenView Earnings Details
8/2/2016Q216($0.20)($0.15)$3.75 million$8.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.19)($0.19)$4.00 million$5.03 millionViewListenView Earnings Details
3/8/2016Q415($0.14)($0.14)$8.90 million$8.50 millionViewListenView Earnings Details
11/3/2015Q315($0.17)($0.08)$5.00 million$12.90 millionViewListenView Earnings Details
8/4/2015Q215($0.22)($0.16)$2.67 million$5.18 millionViewListenView Earnings Details
5/7/2015Q414($0.18)($0.21)$16.00 million$2.18 millionViewListenView Earnings Details
3/3/2015Q4($0.27)($0.25)$2.50 million$8.25 millionViewN/AView Earnings Details
11/4/2014Q314($0.27)($0.24)$1.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.25)($0.29)$1.05 millionViewN/AView Earnings Details
5/7/2014Q114($0.25)($0.25)$0.43 millionViewN/AView Earnings Details
3/4/2014Q4 13($0.25)($0.19)$5.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.29)($0.27)$260.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.30)($0.26)$0.53 million$1.40 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.30)($0.29)$1.73 millionViewN/AView Earnings Details
3/5/2013Q4 2012($0.32)($0.30)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.36)$0.84 millionViewN/AView Earnings Details
8/7/2012($0.34)($0.35)ViewN/AView Earnings Details
5/1/2012($0.33)($0.32)ViewN/AView Earnings Details
3/6/2012($0.28)($0.36)ViewN/AView Earnings Details
11/1/2011($0.28)($0.25)ViewN/AView Earnings Details
8/2/2011($0.36)($0.37)ViewN/AView Earnings Details
5/3/2011($0.36)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Rigel Pharmaceuticals (NASDAQ:RIGL) Earnings Estimates

2017 EPS Consensus Estimate: ($0.56)
2018 EPS Consensus Estimate: ($0.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.13)($0.13)($0.13)
Q1 20181($0.13)($0.13)($0.13)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Rigel Pharmaceuticals (NASDAQ:RIGL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.21%
Institutional Ownership Percentage: 74.51%
Insider Trades by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/3/2017Ryan D MaynardCFOSell100,000$3.90$390,000.00View SEC Filing  
7/5/2017Anne-Marie DuliegeInsiderSell5,000$2.69$13,450.00View SEC Filing  
8/30/2016Donald G PayanEVPSell5,303$4.00$21,212.00View SEC Filing  
4/1/2015Donald G PayanEVPSell10,000$3.75$37,500.00View SEC Filing  
12/18/2014Dolly VanceEVPSell1,000$2.22$2,220.00View SEC Filing  
9/3/2014Donald G PayanEVPSell20,000$2.56$51,200.00View SEC Filing  
11/19/2013Bvf Partners P/Ilmajor shareholderSell484,622$2.64$1,279,402.08View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy32,700$3.47$113,469.00View SEC Filing  
9/13/2012Dolly VanceEVPSell4,151$10.43$43,294.93View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rigel Pharmaceuticals (NASDAQ RIGL) News Headlines

Source:
DateHeadline
Rigel Announces Departure of Chief Financial OfficerRigel Announces Departure of Chief Financial Officer
finance.yahoo.com - December 15 at 11:55 AM
Rigel Pharmaceuticals (RIGL) Coverage Initiated at Cantor FitzgeraldRigel Pharmaceuticals (RIGL) Coverage Initiated at Cantor Fitzgerald
www.americanbankingnews.com - December 14 at 7:06 PM
Short Interest in Rigel Pharmaceuticals, Inc. (RIGL) Expands By 26.5%Short Interest in Rigel Pharmaceuticals, Inc. (RIGL) Expands By 26.5%
www.americanbankingnews.com - December 13 at 1:10 AM
Rigel Pharmaceuticals, Inc. (RIGL) Given Consensus Rating of "Hold" by AnalystsRigel Pharmaceuticals, Inc. (RIGL) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 11 at 1:58 PM
Rigel Pharmaceuticals (RIGL) Given a $7.00 Price Target by HC Wainwright AnalystsRigel Pharmaceuticals (RIGL) Given a $7.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - December 11 at 8:30 AM
Rigel Pharma (RIGL) to Present One-Year Efficacy, Safety Results for Fostamatinib in ITP at ASH - StreetInsider.comRigel Pharma (RIGL) to Present One-Year Efficacy, Safety Results for Fostamatinib in ITP at ASH - StreetInsider.com
www.streetinsider.com - December 10 at 3:40 PM
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
www.prnewswire.com - December 8 at 8:49 PM
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock OptionsImplied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
finance.yahoo.com - December 7 at 11:50 AM
Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : December 6, 2017Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : December 6, 2017
finance.yahoo.com - December 6 at 11:43 AM
ETFs with exposure to Rigel Pharmaceuticals, Inc. : December 5, 2017ETFs with exposure to Rigel Pharmaceuticals, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:36 PM
Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 5:01 PM
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire (press release)Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire (press release)
www.prnewswire.com - November 19 at 8:48 AM
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - November 18 at 11:22 AM
Rigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Rating of "Hold" from BrokeragesRigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 16 at 11:54 AM
Rigel Pharmaceuticals, Inc. (RIGL) Raised to "Buy" at Zacks Investment ResearchRigel Pharmaceuticals, Inc. (RIGL) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 6:30 AM
Rigel Pharmaceuticals, Inc. Expected to Post FY2017 Earnings of ($0.56) Per Share (RIGL)Rigel Pharmaceuticals, Inc. Expected to Post FY2017 Earnings of ($0.56) Per Share (RIGL)
www.americanbankingnews.com - November 10 at 1:54 PM
EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q3 Earnings Report
www.rttnews.com - November 9 at 12:33 PM
Rigel Pharmaceuticals, Inc. to Host Earnings CallRigel Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 12:33 PM
Rigel Pharmaceuticals, Inc. to Host Earnings CallRigel Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 12:33 PM
Rigel Announces Third Quarter 2017 Financial Results and Provides Company UpdateRigel Announces Third Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - November 9 at 12:33 PM
Rigel reports 3Q lossRigel reports 3Q loss
finance.yahoo.com - November 9 at 12:33 PM
Edited Transcript of RIGL earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of RIGL earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 9 at 12:33 PM
Equities Analysts Set Expectations for Rigel Pharmaceuticals, Inc.s Q1 2018 Earnings (RIGL)Equities Analysts Set Expectations for Rigel Pharmaceuticals, Inc.'s Q1 2018 Earnings (RIGL)
www.americanbankingnews.com - November 9 at 11:12 AM
Rigel Pharmaceuticals, Inc. (RIGL) CFO Ryan D. Maynard Sells 100,000 SharesRigel Pharmaceuticals, Inc. (RIGL) CFO Ryan D. Maynard Sells 100,000 Shares
www.americanbankingnews.com - November 8 at 12:22 AM
Rigel Pharmaceuticals, Inc. (RIGL) Announces  Earnings ResultsRigel Pharmaceuticals, Inc. (RIGL) Announces Earnings Results
www.americanbankingnews.com - November 7 at 9:28 PM
Rigel Pharmaceuticals, Inc. (RIGL) Receives New Coverage from Analysts at HC WainwrightRigel Pharmaceuticals, Inc. (RIGL) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - November 6 at 8:08 AM
Rigel Welcomes Gregg Lapointe to Board of DirectorsRigel Welcomes Gregg Lapointe to Board of Directors
finance.yahoo.com - November 4 at 11:43 AM
Rigel Pharmaceuticals, Inc. (RIGL) to Release Quarterly Earnings on TuesdayRigel Pharmaceuticals, Inc. (RIGL) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 1 at 8:08 PM
Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial ResultsRigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results
finance.yahoo.com - October 31 at 8:41 AM
Rigel Pharmaceuticals, Inc. (RIGL) Short Interest UpdateRigel Pharmaceuticals, Inc. (RIGL) Short Interest Update
www.americanbankingnews.com - October 26 at 1:40 AM
Rigel Pharmaceuticals, Inc. (RIGL) to Release Earnings on MondayRigel Pharmaceuticals, Inc. (RIGL) to Release Earnings on Monday
www.americanbankingnews.com - October 23 at 9:20 AM
Rigel Pharmaceuticals, Inc. (RIGL) Receives Average Rating of "Hold" from AnalystsRigel Pharmaceuticals, Inc. (RIGL) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 12:52 PM
Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 20% Using Options - TheStreet.comCommit To Purchase Rigel Pharmaceuticals At $2.50, Earn 20% Using Options - TheStreet.com
www.thestreet.com - October 14 at 7:20 AM
Rigel Pharmaceuticals, Fostamatinib Clinical Trials and Pipeline ReviewRigel Pharmaceuticals, Fostamatinib Clinical Trials and Pipeline Review
finance.yahoo.com - October 11 at 7:10 AM
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional SharesRigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
finance.yahoo.com - October 11 at 7:10 AM
Zacks Investment Research Upgrades Rigel Pharmaceuticals, Inc. (RIGL) to HoldZacks Investment Research Upgrades Rigel Pharmaceuticals, Inc. (RIGL) to Hold
www.americanbankingnews.com - October 8 at 9:16 PM
Rigel Pharma (RIGL) Prices 18.1M Share Common Offering at $3.35/ShRigel Pharma (RIGL) Prices 18.1M Share Common Offering at $3.35/Sh
www.streetinsider.com - October 6 at 6:49 AM
Here's Why Rigel Pharmaceuticals, Inc. Reversed Course TodayHere's Why Rigel Pharmaceuticals, Inc. Reversed Course Today
finance.yahoo.com - October 6 at 6:49 AM
Heres Why Rigel Pharmaceuticals, Inc. Reversed Course TodayHere's Why Rigel Pharmaceuticals, Inc. Reversed Course Today
www.fool.com - October 4 at 4:47 PM
Rigel Pharmaceuticals (RIGL) Buy Rating Reiterated at Jefferies Group LLCRigel Pharmaceuticals' (RIGL) Buy Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - October 4 at 12:38 PM
Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Posts Wider-Than-Expected Loss - NasdaqMid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Posts Wider-Than-Expected Loss - Nasdaq
www.nasdaq.com - October 3 at 11:46 AM
Mid-Afternoon Market Update: Dow Gains 130 Points; CyberOptics Shares Plunge - BenzingaMid-Afternoon Market Update: Dow Gains 130 Points; CyberOptics Shares Plunge - Benzinga
www.benzinga.com - October 3 at 11:46 AM
FDA Update Keeps Rigel Pharmaceuticals Above Water - 24/7 Wall St.FDA Update Keeps Rigel Pharmaceuticals Above Water - 24/7 Wall St.
247wallst.com - October 3 at 11:46 AM
Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers - TheStreet.comDimension Shares Rise On Sale to Ultragenyx - Biotech Movers - TheStreet.com
www.thestreet.com - October 3 at 11:46 AM
Rigel shares soar 14% on positive data in early study of treatment for rare form of anemia - MarketWatchRigel shares soar 14% on positive data in early study of treatment for rare form of anemia - MarketWatch
www.marketwatch.com - October 3 at 11:46 AM
Rigel Pharma: Fostamatinib Meets Endpoint In Stage 1 Of AIHA Phase 2 Study - NasdaqRigel Pharma: Fostamatinib Meets Endpoint In Stage 1 Of AIHA Phase 2 Study - Nasdaq
www.nasdaq.com - October 3 at 11:46 AM
Heres Why Rigel Pharmaceuticals, Inc. Is Jumping Higher TodayHere's Why Rigel Pharmaceuticals, Inc. Is Jumping Higher Today
www.fool.com - October 2 at 1:50 PM
ETF Preview: ETFs, Futures Point Positive Despite Spanish Protests, Las Vegas Shooting Dampening Sentiment - NasdaqETF Preview: ETFs, Futures Point Positive Despite Spanish Protests, Las Vegas Shooting Dampening Sentiment - Nasdaq
www.nasdaq.com - October 2 at 9:55 AM
Pre-Market Most Active for Oct 2, 2017 : CZR, MGM, SIRI, SNCR, ROKU, STM, MNKD, RIGL, BAC, NOK, CHK, BABA - NasdaqPre-Market Most Active for Oct 2, 2017 : CZR, MGM, SIRI, SNCR, ROKU, STM, MNKD, RIGL, BAC, NOK, CHK, BABA - Nasdaq
www.nasdaq.com - October 2 at 9:55 AM
Rigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Recommendation of "Hold" from AnalystsRigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 27 at 12:54 PM

SEC Filings

Rigel Pharmaceuticals (NASDAQ:RIGL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rigel Pharmaceuticals (NASDAQ:RIGL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rigel Pharmaceuticals (NASDAQ RIGL) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.